Medtronic’s Evolut valve reduces dysfunction, improves quality of life in women with severe aortic stenos

Medtronic, the global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, looking exclusively at women. The findings showed the Evolut self-expanding valve (SEV) was associated with significantly less bioprosthetic valve dysfunction (BVD) and improved quality of life for women with symptomatic severe aortic stenosis (AS). The data was presented as a late-breaking trial at the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) 2024.

Symptomatic severe AS can be fatal if left untreated and the average patient survival is two years without treatment. Despite women's longer life expectancy, once impacted by severe AS they suffer from higher mortality than men, even after matching for age. Both TAVR and surgical aortic valve replacement (SAVR) are options for women to treat AS. However, due to their smaller aortic annuli, women can often receive a valve replacement that does not properly fit their anatomy.

Results demonstrated the primary clinical endpoint for composite of death, disabling stroke, or heart failure rehospitalization was similar amongst women with AS and small annulus randomized to balloon-expandable valve (BEV) or SEV at one year. However, , compared to a balloon-expandable valve, the Evolut SEV was associated with significantly less BVD (8.4% vs. 41.8% at 12 months), less prosthesis-patient mismatch (11.1% vs. 37.4% at 12 months), less mild or greater total aortic regurgitation (12.3% vs. 18.8% at 12 months), and improved quality of life in women with AS and small annulus. 

"This study is a major milestone for women, who have historically been excluded and underrepresented in clinical trials," said Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI, Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials, Mount Sinai School of Medicine and co-lead investigator of the SMART Trial. "This subset of the data reinforces that compared to balloon-expandable valves, the Evolut TAVR system was associated with significantly less bioprosthetic valve dysfunction and improved quality of life in women."

The SMART trial is the largest TAVR trial to date to enroll primarily women (87%) and was designed to better understand how the two most commonly used TAVR systems perform in patients with small aortic annuli (SAA) which typically are women. SMART is an international, prospective, multi-center, randomized (1:1) post-market trial comparing the safety and performance of SEV versus BEV TAVR in patients with symptomatic severe AS and SAA. The trial randomized and treated 637 women across more than 80 sites worldwide. Eligible patients had a computed tomography aortic valve annulus area of ≤430 mm2 and suitable anatomy for transfemoral TAVR with both an Evolut PRO/PRO+/FX or a SAPIEN 3™/3 Ultra™ valve.

The data presented today at EuroPCR provides meaningful insights into the benefits Evolut TAVR has for women, which is part of the Cardiovascular Portfolio at Medtronic. This new analysis reinforces TAVR's effectiveness as a solution for achieving superior valve performance while also highlighting the importance of clinical evidence to inform the best treatment approaches for women."

Roxana Mehran, MD

Source:

Medtronic

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
​MGI Tech shares new data on core DNEBSEQ technology and showcases latest sequencing innovations at ESHG 2024